Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole prophylaxis for invasive fungal disease in childhood acute leukemia
ChiCTR2200064677Phase 4Not yet recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of posaconazole in invasive mycoses and Acute Leukaemia, sponsored by Beijing Children's Hospital. Primary endpoints: Incidence of invasive fungal disease and Success rate of plasma concentration of posaconazole. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
posaconazole
03
Conditions
invasive mycosesAcute Leukaemia
Beyond the preview
Go deeper on ChiCTR2200064677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064677.